Search company, investor...

Predict your next investment

Venture Capital
gbsventures.com.au

Investments

93

Portfolio Exits

14

Funds

5

About GBS Venture Partners

GBS Venture Partners (GBS) is a life science venture capital group resulting from a November 2002 management buyout of Rothschild Bioscience Managers Limited from NM Rothschild & Sons (Aust) Ltd.

Headquarters Location

Harley House Level 5

Vic 3000,

Australia

Want to inform investors similar to GBS Venture Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest GBS Venture Partners News

Moximed Raises $40 Million to Advance Implantable Shock Absorber for Knee Osteoarthritis

Aug 18, 2022

Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), announces $40 million in Series C equity and debt financing. The round was led by Advent Life Sciences and also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, Gilde Healthcare, GBS Venture Partners and Morgenthaler Ventures, with debt financing provided by Runway Growth Capital. Proceeds from the financing will be used to gain the necessary regulatory approvals and establish commercial infrastructure for the MISHA Knee System, the world’s first implantable shock absorber (ISA) for the knee. Dedicated to helping people with mild to moderate osteoarthritis preserve their knee joints while living active lives, Moximed utilized the clinically established benefits of weight load reduction on diseased joints to design the MISHA Knee System. Implanted during an outpatient procedure, the MISHA Knee System has been shown to alleviate pain, improve function, and potentially delay the need for total knee replacement in some patients. Results from Moximed’s recently completed Calypso pivotal study of the device will be presented at the Orthopedic Summit (OSET) in Boston on September 22, 2022. “Once non-surgical care is exhausted, patients suffering from knee OA become very frustrated with the lack of options to address their continued pain and disability. As their surgeon, I share their frustration. When, despite our best medical management efforts, my patients are faced with enduring chronic pain or submitting to early joint replacement, I’m left offering them options that they really don’t want,” said Anil Ranawat, M.D., Chief, Hip and Knee Division of Sports Medicine Institute, Hospital for Special Surgery in New York. Osteoarthritis (OA) is a common, debilitating condition that develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives to live. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life. “We’ve listened carefully to patients, and their surgeons, and we’re excited to develop a solution that meets their needs,” said Anton Clifford, PhD, Moximed CEO. “Patients deserve treatment options that allow them to live life to their fullest abilities, whether it’s caring for a loved one, returning to a favorite sport, or simply getting through their working day. Results from our pivotal study show the MISHA Knee System not only alleviates pain and OA-induced activity limitations, but also offers complete preservation of the knee, an outpatient procedure, and early weight bearing. These are all strong preferences expressed by our patient population.” “Working people who have knee OA have been waiting for a solution that falls between conservative care and eventual joint replacement. Moximed has the potential to fill this gap in knee OA treatment with the MISHA Knee System, and we are excited to further support Moximed’s efforts to alter the treatment paradigm for millions of Americans,” said Shahzad Malik, MD, General Partner, Advent Life Sciences. [Source(s): Moximed, Business Wire]

GBS Venture Partners Investments

93 Investments

GBS Venture Partners has made 93 investments. Their latest investment was in Moximed as part of their Series C - II on August 8, 2022.

CBI Logo

GBS Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/16/2022

Series C - II

Moximed

No

2

3/16/2017

Series C

Moximed

$50M

No

3

1/7/2016

Series B

Elastagen

$9.13M

No

2

6/8/2015

Series E - II

Subscribe to see more

$99M

Subscribe to see more

10

5/5/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/16/2022

3/16/2017

1/7/2016

6/8/2015

5/5/2015

Round

Series C - II

Series C

Series B

Series E - II

Series B

Company

Moximed

Moximed

Elastagen

Subscribe to see more

Subscribe to see more

Amount

$50M

$9.13M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

3

2

10

10

GBS Venture Partners Portfolio Exits

14 Portfolio Exits

GBS Venture Partners has 14 portfolio exits. Their latest portfolio exit was Ivantis on November 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2021

Acquired

$99M

5

2/7/2018

Acquired

$99M

1

11/1/2017

Acquired

$99M

1

9/8/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/2/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2021

2/7/2018

11/1/2017

9/8/2017

3/2/2017

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

5

1

1

10

10

GBS Venture Partners Fund History

5 Fund Histories

GBS Venture Partners has 5 funds, including GBS Bioventures IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/31/2009

GBS Bioventures IV

Multi-Stage Venture Capital

Closed

$81.93M

1

4/1/2005

GBS Bioventures III

Subscribe to see more

Subscribe to see more

$99M

10

10/1/2002

Genesis Fund

Subscribe to see more

Subscribe to see more

$99M

10

7/31/2001

GBS Bioventures II

Subscribe to see more

Subscribe to see more

$99M

10

10/1/1998

Australian Bioscience Trust

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/31/2009

4/1/2005

10/1/2002

7/31/2001

10/1/1998

Fund

GBS Bioventures IV

GBS Bioventures III

Genesis Fund

GBS Bioventures II

Australian Bioscience Trust

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$81.93M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

GBS Venture Partners Team

4 Team Members

GBS Venture Partners has 4 team members, including , .

Name

Work History

Title

Status

Geoffrey E. Brooke

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Geoffrey E. Brooke

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.